Alzinova submits FDA amendment for Phase 2a trial of Alzheimer's vaccine ALZ-101

• Alzinova submitted an FDA amendment for its Phase 2a ADVANCE trial of ALZ-101 in early Alzheimer's disease, moving preparations toward enrollment.
• The study will evaluate the therapeutic vaccine in approximately 120 participants across the United States, European Union and United Kingdom.
• Seven US trial sites have been selected, with first participant enrollment targeted around the turn of 2026/2027.
• Phase 1b showed encouraging immune responses; ADVANCE will investigate whether the vaccine delivers meaningful clinical benefits.
• The ADVANCE study design will be presented at the Clinical Trials on Alzheimer's Disease conference in Boston in November 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzinova AB published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.